In a report issued on May 5, Leah R. Cann from Brookline Capital Markets maintained a Buy rating on Intellia Therapeutics (NTLA – Research Report), with a price target of $91.00. The company’s shares closed last Friday at $47.57, close to its 52-week low of $44.00.
According to TipRanks.com, Cann is a 1-star analyst with an average return of -0.6% and a 39.2% success rate. Cann covers the Healthcare sector, focusing on stocks such as Crispr Therapeutics AG, Syros Pharmaceuticals, and Kymera Therapeutics.
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Intellia Therapeutics with a $123.69 average price target, a 147.2% upside from current levels. In a report issued on May 6, Evercore ISI also maintained a Buy rating on the stock with a $75.00 price target.
See Insiders’ Hot Stocks on TipRanks >>
Based on Intellia Therapeutics’ latest earnings release for the quarter ending December 31, the company reported a quarterly revenue of $12.85 million and GAAP net loss of $81.24 million. In comparison, last year the company earned revenue of $6.6 million and had a GAAP net loss of $42.19 million.
Based on the recent corporate insider activity of 37 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of NTLA in relation to earlier this year.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Intellia Therapeutics, Inc. engages in the development of gene editing-based therapies. It provides scientific expertise, clinical development, and intellectual property position to unlock broad therapeutic applications of CRISPR or Cas9 genome editing and develop a potential new drug class. The company was founded by Andrew May, Luciano Marraffini, Rodolphe Barrangou, Nessan Bermingham, Rachel Haurwitz, Erik Sontheimer, Jennifer Doudna, and Derrick Rossi in May 2014 and is headquartered in Cambridge, MA.
Read More on NTLA:
- BMO Capital Sticks to Their Hold Rating for WildBrain (WLDBF)
- TransAlta (TAC) Received its Third Buy in a Row
- BMO Capital Thinks TELUS International (CDA)’s Stock is Going to Recover
- BMO Capital Sticks to Their Hold Rating for Paycor HCM (PYCR)
- BMO Capital Believes Vistra Energy (VST) Won’t Stop Here
